Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Mice humanized by syntenic replacement with full-length NLRP3 disease-associated variants model the clinical cryopyrinopathy continuum
John N. Snouwaert, MyTrang Nguyen, Christopher A. Gabel, Ivona Aksentijevich, Jenny P.-Y. Ting, Beverly H. Koller
John N. Snouwaert, MyTrang Nguyen, Christopher A. Gabel, Ivona Aksentijevich, Jenny P.-Y. Ting, Beverly H. Koller
View: Text | PDF
Research Article Genetics Immunology Inflammation

Mice humanized by syntenic replacement with full-length NLRP3 disease-associated variants model the clinical cryopyrinopathy continuum

  • Text
  • PDF
Abstract

Next-generation sequencing technologies are increasingly used to diagnose genetic disorders, particularly immunological diseases with broad and overlapping immune dysregulation. Cryopyrin-associated periodic syndromes (CAPS) are caused by gain-of-function mutations in NLRP3 and include 3 autoinflammatory diseases spanning a continuum of severity: familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and neonatal-onset multisystem inflammatory disease (NOMID). Linking NLRP3 variants to protein dysfunction and clinical phenotype remains challenging because of genetic modifiers and environmental factors. We report the generation and phenotyping of 5 mouse lines expressing either the common human NLRP3 allele or 1 of 4 CAPS mutations spanning the disease spectrum from FCAS to NOMID. In these lines, the murine Nlrp3 locus is replaced by syntenic integration of the human NLRP3 locus, yielding 1 line with the common allele and 4 lines each carrying a distinct CAPS mutation. Unlike models in which a human mutation is introduced into the mouse protein, these lines recapitulate the spectrum of disease severity observed in humans. These findings support a model in which evaluation of nonsynonymous mutations in mice is optimized when introduced in the context of the human gene. This suggests that species-specific regulation and/or intramolecular epistasis may impact modeling of disease-associated variants.

Authors

John N. Snouwaert, MyTrang Nguyen, Christopher A. Gabel, Ivona Aksentijevich, Jenny P.-Y. Ting, Beverly H. Koller

×

Figure 3

IL-1β release from blood of NLRP3-mutant mice and sensitivity to CP-456,773.

Options: View larger image (or click on image) Download as PowerPoint
IL-1β release from blood of NLRP3-mutant mice and sensitivity to CP-456,...
Blood was collected from mice of the indicated genotype and exposed to LPS or LPS followed by ATP. In some experiments, blood was incubated throughout at 32°C rather than the standard 37°C. (A) Blood from mice homozygous for the common NLRP3 allele (hNLRP3) released IL-1β after exposure to LPS and ATP. CP-456,773 inhibited release in a concentration-dependent manner. While release decreased when the assay was performed at 32°C, the IC50 was temperature independent. (B) No IL-1β release after LPS exposure of blood from mice homozygous for the L307P allele was observed at 37°C (solid line). In contrast, IL-1β release occurred at 32°C (dashed line), but this was not inhibited by CP-456,773. (C) IL-1β release from L307P blood was observed at 37°C when LPS exposure was followed by ATP (dashed/dotted line). This LPS/ATP-mediated release was insensitive to CP-456,773. (D–F) LPS exposure of blood from mice heterozygous for the D305N (D), F311S (E), and Y527C (F) alleles resulted in measurable IL-1β release. Release by all 3 mutants was inhibited in a concentration-dependent manner by CP-456,773. (G and H) Total white blood cell count (WBC) and leukocyte subpopulations in blood collected from the indicated number of hNLRP3, D305N, F311S, and Y572C mice were determined by CBC. (G) Thousands of cells per cubic milliliter (K/μL), with statistical evaluation detailed in Supplemental Table 4. (H) Leukocyte subpopulations as a percentage of total WBC, with differences between CAPS mice evaluated by 2-tailed unpaired t test (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts